Keywords
RimonabantMedicinePlaceboOverweightInternal medicinePopulationBody mass indexWeight lossEndocrinologyGastroenterologyCannabinoid receptorAntagonistObesityReceptor
Affiliated Institutions
Related Publications
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin–resistance syndrome, at present defined as the metabolic syndrome, whose limits were recently set. ...
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body we...
Body Fat Content and 25-Hydroxyvitamin D Levels in Healthy Women
Obesity is associated with alterations in the vitamin D endocrine system. Lower levels of serum 25-hydroxyvitamin D (25-OHD) in morbidly obese individuals may be secondary to an...
Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study
Prevalence of fatty liver was 29% in overweight/obese and 5% in normal-weight adults. Differences in factors associated with fatty liver were seen between these two groups: alco...
Dominant and diet-responsive groups of bacteria within the human colonic microbiota
Abstract The populations of dominant species within the human colonic microbiota can potentially be modified by dietary intake with consequences for health. Here we examined the...
Publication Info
- Year
- 2005
- Type
- article
- Volume
- 365
- Issue
- 9468
- Pages
- 1389-1397
- Citations
- 1486
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1486
OpenAlex
Cite This
Luc F. Van Gaal,
Aila Rissanen,
André Scheen
et al.
(2005).
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
The Lancet
, 365
(9468)
, 1389-1397.
https://doi.org/10.1016/s0140-6736(05)66374-x
Identifiers
- DOI
- 10.1016/s0140-6736(05)66374-x